Envestnet Asset Management Inc. Raises Stake in Agilent Technologies, Inc. (NYSE:A)

Envestnet Asset Management Inc. increased its position in shares of Agilent Technologies, Inc. (NYSE:AFree Report) by 43.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 633,324 shares of the medical research company’s stock after acquiring an additional 190,394 shares during the quarter. Envestnet Asset Management Inc. owned approximately 0.22% of Agilent Technologies worth $88,051,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently modified their holdings of A. MV Capital Management Inc. lifted its holdings in shares of Agilent Technologies by 120.7% in the 4th quarter. MV Capital Management Inc. now owns 192 shares of the medical research company’s stock worth $27,000 after acquiring an additional 105 shares during the last quarter. VisionPoint Advisory Group LLC acquired a new stake in shares of Agilent Technologies in the fourth quarter valued at approximately $29,000. Baystate Wealth Management LLC boosted its stake in Agilent Technologies by 107.3% during the 4th quarter. Baystate Wealth Management LLC now owns 257 shares of the medical research company’s stock worth $36,000 after purchasing an additional 133 shares during the period. Rosenberg Matthew Hamilton grew its holdings in shares of Agilent Technologies by 51.1% during the fourth quarter. Rosenberg Matthew Hamilton now owns 284 shares of the medical research company’s stock worth $39,000 after buying an additional 96 shares during the last quarter. Finally, Turtle Creek Wealth Advisors LLC purchased a new position in shares of Agilent Technologies in the 4th quarter valued at approximately $39,000.

Agilent Technologies Stock Up 0.1 %

Shares of NYSE A opened at $132.98 on Monday. The firm has a market cap of $38.80 billion, a P/E ratio of 31.44, a price-to-earnings-growth ratio of 4.55 and a beta of 1.07. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.64 and a current ratio of 2.15. Agilent Technologies, Inc. has a 1 year low of $96.80 and a 1 year high of $155.35. The firm’s 50 day moving average price is $142.11 and its 200 day moving average price is $137.99.

Agilent Technologies (NYSE:AGet Free Report) last posted its quarterly earnings data on Wednesday, May 29th. The medical research company reported $1.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.19 by $0.03. Agilent Technologies had a return on equity of 26.25% and a net margin of 18.84%. The business had revenue of $1.57 billion for the quarter, compared to analysts’ expectations of $1.58 billion. During the same quarter last year, the firm earned $1.27 earnings per share. The business’s revenue was down 8.4% on a year-over-year basis. As a group, sell-side analysts anticipate that Agilent Technologies, Inc. will post 5.25 earnings per share for the current year.

Agilent Technologies Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 24th. Investors of record on Tuesday, July 2nd will be given a $0.236 dividend. The ex-dividend date of this dividend is Tuesday, July 2nd. This represents a $0.94 annualized dividend and a dividend yield of 0.71%. Agilent Technologies’s dividend payout ratio is presently 22.22%.

Insider Activity at Agilent Technologies

In other news, CEO Padraig Mcdonnell sold 1,958 shares of the company’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $130.00, for a total transaction of $254,540.00. Following the completion of the sale, the chief executive officer now directly owns 25,185 shares in the company, valued at approximately $3,274,050. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, CEO Padraig Mcdonnell sold 1,958 shares of Agilent Technologies stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $130.00, for a total value of $254,540.00. Following the transaction, the chief executive officer now directly owns 25,185 shares of the company’s stock, valued at approximately $3,274,050. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Philip Binns sold 2,827 shares of the stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $147.54, for a total transaction of $417,095.58. Following the sale, the senior vice president now directly owns 9,997 shares of the company’s stock, valued at approximately $1,474,957.38. The disclosure for this sale can be found here.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Evercore ISI reduced their price target on Agilent Technologies from $145.00 to $126.00 and set an “in-line” rating for the company in a report on Thursday, May 30th. UBS Group reduced their price objective on shares of Agilent Technologies from $155.00 to $141.00 and set a “neutral” rating for the company in a research note on Thursday, May 30th. Oppenheimer boosted their price objective on shares of Agilent Technologies from $67.00 to $90.00 and gave the stock an “outperform” rating in a report on Tuesday, March 26th. JPMorgan Chase & Co. dropped their target price on shares of Agilent Technologies from $165.00 to $155.00 and set an “overweight” rating for the company in a report on Thursday, May 30th. Finally, Bank of America reissued a “neutral” rating and set a $134.00 price target (down previously from $145.00) on shares of Agilent Technologies in a research note on Thursday, May 30th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $136.50.

Read Our Latest Stock Analysis on Agilent Technologies

Agilent Technologies Profile

(Free Report)

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

Read More

Institutional Ownership by Quarter for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.